Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tylosin tartrate is a macrolide antibiotic widely used in veterinary medicine to treat a variety of bacterial infections in livestock, poultry, and companion animals. Originally isolated from the soil bacterium *Streptomyces fradiae* by Eli Lilly in 1961, it exerts its bacteriostatic effect by reversibly binding to the 50S subunit of the bacterial ribosome, thereby inhibiting protein synthesis. It is highly effective against Gram-positive bacteria and *Mycoplasma* species, and is commonly indicated for chronic respiratory disease (CRD) in chickens, infectious sinusitis in turkeys, swine dysentery, and bovine respiratory complex. It is administered orally via drinking water or feed, as well as through intramuscular or subcutaneous injection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tylosin tartrate.